Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes nitrofurantoin combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A method of compounding a topical composition includes combining lidocaine and prilocaine, 2.5%/2.5%, cream, diclofenac sodium, 1.5%, topical solution, lidocaine hydrochloride, 4%, topical solution, diclofenac sodium USP powder, lidocaine hydrochloride USP monohydrate powder, and prilocaine hydrochloride USP powder and mixing to generate a cream.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A method of treating a fungal infection may include formulating a topical treatment solution comprising combining itraconazole oral solution, 10 mg/mL, and a diluent. The itraconazole oral solution, 10 mg/mL, may include propylene glycol and at least one of cherry flavor or caramel flavor. The method may also include topically administering the topical treatment solution to the subject by contacting an infected skin surface of the subject with the topical treatment solution.

Abstract: A method of compounding a topical composition includes combining lidocaine and prilocaine, 2.5%/2.5%, cream, diclofenac sodium, 1.5%, topical solution, lidocaine hydrochloride, 4%, topical solution, diclofenac sodium USP powder, lidocaine hydrochloride USP monohydrate powder, and prilocaine hydrochloride USP powder and mixing to generate a cream.

Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.

Abstract: A method of treating or preventing one or both of a bacterial infection or fungal infection of a foot of a subject includes combining a diluent and at least one of a clindamycin solution or an erythromycin solution to form a footbath solution. The method may further include topically administering the footbath solution to the subject. Administering may include contacting with the footbath solution a skin area of the foot of the subject that is infected or suspected to be infected.

Abstract: A method of formulating a topical composition may include combining a powder including an antimicrobial pharmaceutical drug and a topical carrier. The powder may include at least a portion of a crushed oral tablet. The crushed oral tablet may include at least a portion of the antimicrobial pharmaceutical drug. The antimicrobial pharmaceutical drug may be selected from voriconazole, fluconazole, linezolid, levofloxacin, ciprofloxacin, or combination thereof.

Abstract: A combination treatment method for treating a bacterial or fungal nail infection may include providing one or more first composition components and one or more second composition component. The first and second composition components may be mixed with diluent to formulate respective first and second topical nail composition. The topical nail compositions may include nail lacquers for application to an infected nail in a thin layer. The one or more first composition components may include mupirocin. The one or more second composition components may include tetracycline, nitrofurantoin, or combination thereof.

Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.

Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A method of treating a hyperkeratotic skin condition includes combining urea powder with a corticosteroid solution comprising a high potency corticosteroid to formulate a compounded topical composition for application to a skin area affected by hyperkeratosis. The corticosteroid solution may be a fluocinolone acetonide solution. The method may also include combining an azole such as clotrimazole.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.

Abstract: A method of treating bacterial or fungal nail infections may include mixing an antibiotic or antifungal injectable medication and a diluent to formulate a topical nail composition. The topical nail composition may be administered directly to a nail affected by the bacterial or fungal infection.

Abstract: A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.